eligibility_summary
Two cohorts. Inclusion: Adults consent. LBCL: CD20+, prior anthracycline+anti‑CD20 and ≥2 lines incl autoHSCT, PET/CT measurable, ECOG 0–1. SLE: 18–70, 2019 EULAR/ACR ≥6 mo, prior steroids+IS±biologics (stable), ANA/dsDNA/Sm+, SLEDAI‑2K ≥7. Exclusions: primary CNS lymphoma/recent other cancer, active HBV/HCV/HIV/syphilis, recent thrombosis or therapeutic anticoag, major CNS/CV disease, pregnancy, prior CAR‑T. SLE add: severe nephritis/high steroids, recent crisis, transplant, live vaccine.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: JWCAR201—an autologous, gene‑modified cellular immunotherapy (CAR‑T) that co-targets CD19 and CD20. Mechanism of action: patient T cells are engineered to express a chimeric antigen receptor that recognizes CD19 and CD20 on B cells, antigen binding triggers T‑cell activation, cytotoxic killing, cytokine release, and in vivo expansion, producing deep B‑cell depletion. Rationale: dual targeting is intended to reduce antigen‑escape seen with single‑antigen (CD19‑only or CD20‑only) therapies. Cells/pathways targeted: CD19+/CD20+ B cells across maturation states—malignant B cells in large B‑cell lymphoma and autoreactive B cells in SLE—leading to B‑cell aplasia and reduction of autoantibody‑producing precursors. Downstream impact includes suppression of B‑cell receptor–driven germinal center activity and humoral autoimmunity.